This site is intended for healthcare professionals
News

FDA approves Fintepla oral solution for treatment of seizures associated with Lennox-Gastaut syndrome.

Read time: 1 mins
Published:30th Mar 2022

UCB announced that Fintpla(fenfluramine) oral solution CIV has been approved in the United States, by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older.

Additionally, the FDA has granted pediatric exclusivity for the product. It is already approved for the treatment of seizures associated with Dravet syndrome in patients two years of age and older in the US and EU.Fenfluramine for LGS is available in the US through a restricted distribution program, called the Risk Evaluation and Mitigation Strategy (REMS) Program.

LGS is a severe childhood-onset developmental and epileptic encephalopathy (DEE) characterized by drug-refractory seizures with high morbidity as well as serious impairment of neurodevelopmental, cognitive, and motor functions. LGS affects an estimated 30,000 – 50,000 patients in the U.S. LGS has far-reaching effects beyond seizures, including issues with communication, psychiatric symptoms, sleep, behavioral challenges, and mobility. Additionally, sudden unexpected death in epilepsy (SUDEP) is a major concern for people living with LGS.

Condition: Lennox Gastaut Syndrome
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.